Whole-body positron emission tomography/computed tomography (PET/CT) with [11C]- and [18F]-labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer.
11C- and 18F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, especially when the serum prostate-specific antigen level is >1.0 ng/mL. 11C- and 18F-choline PET/CT have more limited roles for the initial staging of prostate cancer and for the detection of tiny lymph node metastases due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The following is a review of the current clinical roles of 11C- and 18F-choline PET/CT in the management of prostate cancer.
Written by:
Kitajima K, Murphy RC, Nathan MA. Are you the author?
Department of Radiology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Reference: Ann Nucl Med. 2013 Apr 30. Epub ahead of print.
doi: 10.1007/s12149-013-0731-7
PubMed Abstract
PMID: 23632880
UroToday.com Prostate Cancer Section
